Idera and BioCryst Merge to Form Rare Disease Company
By Natasha Piper
Pharma Deals Review: Vol 2018 Issue 2 (Table of Contents)
Published: 1 Feb-2018
DOI: 10.3833/pdr.v2018.i2.2300 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
BioCryst Pharmaceuticals and Idera Pharmaceuticals have entered into a definitive merger agreement to form a rare disease-focused company under a new name...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS